Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Raw Materials: 2009-2024

Historic Raw Materials for Fresenius Medical Care AG (FMS) over the last 16 years, with FY2024 value amounting to $451.8 million.

  • Fresenius Medical Care AG's Raw Materials fell 812.97% to $446.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $446.1 million, marking a year-over-year decrease of 812.97%. This contributed to the annual value of $451.8 million for FY2024, which is 694.82% down from last year.
  • Per Fresenius Medical Care AG's latest filing, its Raw Materials stood at $451.8 million for FY2024, which was down 694.82% from $485.6 million recorded in FY2023.
  • Fresenius Medical Care AG's 5-year Raw Materials high stood at $583.7 million for FY2022, and its period low was $451.8 million during FY2024.
  • Over the past 5 years, Fresenius Medical Care AG's median Raw Materials value was $517.2 million (recorded in 2021), while the average stood at $515.7 million.
  • In the last 5 years, Fresenius Medical Care AG's Raw Materials soared by 2072.37% in 2020 and then crashed by 1680.89% in 2023.
  • Annual analysis of 5 years shows Fresenius Medical Care AG's Raw Materials stood at $540.2 million in 2020, then fell by 4.27% to $517.2 million in 2021, then rose by 12.87% to $583.7 million in 2022, then dropped by 16.81% to $485.6 million in 2023, then fell by 6.95% to $451.8 million in 2024.
  • Its Raw Materials stands at $451.8 million for FY2024, versus $485.6 million for FY2023 and $583.7 million for FY2022.